

DAFTAR PUSTAKA

1. Gudjonsson JE, Elder JT. Psoriasis. In: Wolff K, Goldmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, editors. Fitzpatrick's dermatology in general medicine. 9th ed. New York: McGraw-Hill. 2019;457–97.
2. Armstrong AW, Read C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. *JAMA network open*. 2020;323(19):1945–1960.
3. Al Qassimi S, Al Brashdi S, Galadari H, Hashim MJ. Global burden of psoriasis - comparison of regional and global epidemiology, 1990 to 2017. *Int J Dermatol*. 2020;59(5):566-571.
4. Prakoeswa S, Hidayati A, Hendaria M, Damayanti D, Citrashanty I. The Profile of Psoriasis Vulgaris Patients: a Descriptive Study. *Berkala Ilmu Kesehatan Kulit dan Kelamin*. 2021;33(3):173–181.
5. Segar D, Karmila ID, Praharsini I, Indira IE. Prevalence and clinical manifestations of patients with psoriasis in RSUP Sanglah from 2017 to 2018. *Intisari Sains Medis*. 2019;10(3):840-844.
6. Korman NJ. Management of psoriasis as a systemic disease: what is the evidence? *Br J Dermatol*. 2020;182(4):840-848.
7. Feldman SR, Tian H, Gilloteau I, Mollon P, Shu M. Economic burden of comorbidities in psoriasis patients in the United States: results from a retrospective U.S. database. *BMC Health Serv Res*. 2017;17(1):1-8.
8. Hassani F, Koraei A, Yaghoobi R, Zarea K. An evaluating of the relationship between body image, body satisfaction, depression, marital quality, and self-esteem in patients with psoriasis. *Psychology, Health & Medicine*. 2020;26(4):1-11.
9. Jankowiak B, Kowalewska B, Kulak EK, Khvorik DF. Stigmatization and Quality of Life in Patients with Psoriasis. *Dermatol Ther (Heidelb)*. 2020;10:285–296.
10. Kowalewska B, Jankowiak B, Cybulski M, Kulak EK, Khvorik DF. Effect of Disease Severity on the Quality of Life and Sense of Stigmatization in Psoriatics. *Clinical, Cosmetic and Investigational Dermatology*. 2021;14:107-121.

11. Nayak PB, Girisha BS, Noronha TM. Correlation between disease severity, family income, and quality of life in psoriasis: a study from South India. *Indian Dermatology Online Journal*. 2018;9(3):165-9.
12. Sarma N. Evidence and suggested therapeutic approach in psoriasis of difficult-to-treat areas: palmoplantar psoriasis, nail psoriasis, scalp psoriasis, and intertriginous psoriasis. *Indian J Dermatol*. 2017;62(2):113-122.
13. Kerkhof PCM, Nestlé FO. Psoriasis. In: Bologna JL, Schaffer JV, Cerroni L, editors. *Dermatology*. 4th ed. London: Elsevier. 2018;138-60.
14. Thappa DM, Malathi M. Topical therapy of psoriasis: Where do we stand? *J Postgrad Med*. 2017;63(4):210-212.
15. Elmetts CA, Korman NJ, Prater EF, Wong EB, Rupani RN, Kivelevitch D, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. *J Am Acad Dermatol*. 2021;84(2):432-470.
16. Caplan A, Fett N, Werth V. Glucocorticoids. In: Wolff K, Goldsmith LA, Katz SI, Gilchrist BA, Paller AS, Leffell DJ, editors. *Fitzpatrick's dermatology in general medicine*. 9th ed. New York: McGraw-Hill. 2019;3388-3394.
17. Nugroho AW. Review: konservasi keanekaragaman hayati melalui tanaman obat dalam hutan di Indonesia dengan teknologi farmasi: potensi dan tantangan. *Jurnal Sains dan Kesehatan*. 2017;1(7):377-383.
18. Bonesi M, Loizzo M.R, Provenzano E, Menichini F, Tundis R. Anti-psoriasis agents from natural plant sources. *Curr. Med. Chem*. 2016;23:1250-1267.
19. Gupta SC, Tyagi AK, Deshmukh PT, Hinojosa M, Prasad S, Aggarwal BB. Downregulation of tumor necrosis factor and other proinflammatory biomarkers by polyphenols. *Arch Biochem Biophys*. 2014;559:91-99.
20. Dias MC, Pinto D, Silva AMS. Plant Flavonoids: Chemical Characteristics and Biological Activity. *Molecules*. 2021;26(53):1-16.
21. Andarina R, Djauhari T. Antioksidan dalam dermatologi. *JKK*. 2017;4(1):39-48.
22. Manzoor MF, Ahsan M, Abdul W. Quercetin-a mini review. *Modern Concepts & Developments in Agronomy*. 2018;1(2):24-28.
23. Miles SL, McFarland M, Niles RM. Molecular and physiological actions of quercetin: need for clinical trials to assess its benefits in human disease.

- Nutrition Reviews. 2014;72(11):720-734.
24. Kumar R, Vijayalakshmi S, Nadanasabapathi S. Health benefits of quercetin. *Defence Life Science Journal*. 2017;2(2):142-151.
 25. Naidu N, Biyani D, Umekar M, Burley V. An Overview of a Versatile Compound: Quercetin. *Int. J. Pharm. Sci. Rev. Res*. 2021;69(1):248-257.
 26. Alizadeh SR, Ebrahimzadeh MA. Quercetin derivatives: Drug design, development, and biological activities, a review. *European Journal of Medicinal Chemistry*. 2022;229:1-10.
 27. Dabholkar N, Rapalli VK, Singhvi G. Potential herbal constituents for psoriasis treatment as protective and effective therapy. *Phytoterapy Research*. 2020:1-16.
 28. Lai Y, Li D, Li C, Muehleisin B, Radek K, Park HJ, et al. The antimicrobial protein REG3A regulates keratinocyte proliferation and differentiation after skin injury. *Immunity*. 2013;37(1):1-12.
 29. Martin DA, Towne JE, Kricorian G, Kletkoka P, Gudjonsson JE, Krueger JG. The emerging role of IL-17 in the pathogenesis of psoriasis: Preclinical and clinical findings. *J invest Dermatol*. 2013;133:17-26.
 30. Vijayalakshmi A, Ravichandiran V, Malarkodi V, Nirmala S, Jayakumari S. Screening of flavonoid "quercetin" from the rhizome of *Smilax china* Linn. for anti-psoriatic activity. *Asian Pacific J Trop Med*. 2012;2:269-275.
 31. Chen H, Lu C, Liu H, Wang M, Zhao H, Yan Y, et al. Quercetin ameliorates imiquimod-induced psoriasis-like skin inflammation in mice via the NF- κ B pathway. *Int. Immunopharmacol*. 2017;48:110-117.
 32. Solikhah R, Purwantoyo E, Rudyatmi E. Aktivitas Antioksidan dan Ekspresi Klorofil Kultivar Singkong di Daerah Wonosobo. *Life Science Journal of Biology*. 2019;8(1):86-95.
 33. Hanna E, Abadi R, Abbas O. Imiquimod in dermatology: an overview. *International Journal of Dermatology*. 2016;55(8):831-844.
 34. Horvath S, Komlodi R, Perkecz A, Pinter E, Gyulai R, Kemeny A. Methodological refinement of Aldara-induced psoriasiform dermatitis model in mice. *Scientific reports*. 2019; 9:1-8.
 35. Choon SE, Ngim CF, Premaa S, Tey KW, Nalini MN. Clinico epidemiological profile, including body mass index of Malaysian children with psoriasis. *Med J Malaysia*. 2016;71(4):171-6.

36. Kaufman BP, Alexis AF. Psoriasis in skin of color: insights into the epidemiology, clinical presentation, genetics, quality-of-life impact, and treatment of psoriasis in non-white racial/ethnic groups. *Am J Clin Dermatol*. 2018;19(3):405-423.
37. Pratiwi KD, Damayanti. Profil psoriasis vulgaris di RSUD Dr. Soetomo Surabaya: studi retropektif. Dalam: *Berkala Ilmu Kesehatan Kulit dan Kelamin – Periodical of Dermatology and Venereology*. 2018;30:248-54.
38. James WD, Berger TG, Elston DM. Seborrheic dermatitis, psoriasis, recalcitrant palmoplantar eruptions, pustular dermatitis, and erythroderma. In: *Andrew's Diseases of the Skin*. Philadelphia: Elsevier. 2016;185-98.
39. Meephansan J, Subpayasarn U, Komine M, Ohtsuki M. Pathogenic role of cytokines and effect of their inhibition in psoriasis. *An Interdiscip Approach to Psoriasis*. 2017;10:25-31.
40. Madonna V, Tanjung C, Roesyanto ID. Ekspresi sitokin interleukin-17 dalam serum pasien psoriasis dan hubungannya. *Repository USU*. 2014;17:61–64.
41. Kilmer PD. Review article: psoriasis. *Journal Theory, Pract Crit*. 2010;11(3):369–73.
42. Rønholt K, Iversen L. Old and new biological therapies for psoriasis. *Int J Mol Sci*. 2017;18(11):1-7.
43. Mahajan R, Handa S. Pathophysiology of psoriasis. *Indian J Dermatol Venereol Leprol*. 2013;79(1):1–9.
44. Gaspari AA, Tying S. New and emerging biologic therapies for moderate-to-severe plaque psoriasis: Mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors. *Dermatol Ther*. 2015;28(4):179–93.
45. Roh SKJ, Park C. Immunohistochemistry for Pathologists: Protocols, Pitfalls, and Tips. *Journal of Pathology and Translational Medicine*. 2016;50:411-418.
46. Suparna MY, Reddy PKS, Sumathy TK, Mysorekar VV. Immunohistochemical Demonstration of Interleukin-17 Positivity in Skin Biopsy Specimens of Patients with Chronic Plaque Psoriasis and its Correlation with Severity of Psoriasis and Associated Metabolic Syndrome and Cardiovascular Changes. *Clinical Dermatology Review*. 2022;6(2):97-102.
47. Amstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis a review. *Journal of American Medical Association*. 2020;323:19.
48. Kelompok Studi Psoriasis Indonesia. *Pedoman Penggunaan Agen Biologik*

untuk Terapi Psoriasis di Indonesia. Perhimpunan Dokter Spesialis Kulit dan Kelamin Indonesia (Perdoski). 2016; 7-8.

49. Hawkes JE, Chan TC, Krueger JG. Mechanisms of allergic diseases psoriasis pathogenesis and the development of novel targeted immune therapies. *J Allergy Clin Immunol*. 2019;140(3):645–53.
50. Li Y, Yao J, Han C, Yang J, Chaudhry MT, Wang S, et al. Quercetin, inflammation and immunity. *Nutrients*. 2016;8(167):1-14.
51. Dabeek WM, Marra MV. Dietary quercetin and kaempferol: bioavailability and potential cardiovascular-related bioactivity in humans. *Nutrients*. 2019;11(10):1-19.
52. Kubo I, Masuoka N, Nihei K, Burgheim B. Manicoba, a quercetin-rich Amazonian dish. *Journal of Food Composition and Analysis*. 2006;19:579–588.
53. Rendon A, Schakel K. Psoriasis pathogenesis and treatment. *International journal of molecular sciences*. 2019;20:1–28.
54. Goldminz AM, Au SC, Kim N, Gottlieb AB, Lizzul PF. NF-kappaB: an essential transcription factor in psoriasis. *Journal of Dermatology of Sciences*. 2013;69(2):89–94.
55. Roh NK, Han SH, Youn HJ, Kim YR, Lee YW, Choe YB, et al. Tissue and serum inflammatory cytokine levels in Korean psoriasis patients: a comparison between plaque and guttate psoriasis. *Ann. Dermatol*. 2015;27(6):738–743.
56. Lowes MA, Farinas MS, Krueger JG. Immunology of Psoriasis. *Annu. Rev. Immunol*. 2019;32:227-255.
57. Menter A, Krueger GG, Paek SY, Kivelevitch D, Adamopoulos IE, Langley RG. Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities. *Dermatol Ther (Heidelb)*. 2021;11:385–400.
58. Dabholkar N, Rapalli VK, Singhvi G. Potential herbal constituents for psoriasis treatment as protective and effective therapy. *Phytotherapy Research*. 2020;1–16.
59. Mobini N, Toussaint S, Kamino H. Noninfectious Erythematous, Papular, and Squamous Diseases. In: Elder DE, Elenitsas R, Johnson BL, Murphy GF, Xu X, editors. *Lever's Histopathology of the Skin*. 10th ed. USA: Wolters Kluwer. 2009;169-203.

60. Hou DD, Zhang W, Gao Y, Sun Y, Wang H, Qi R, et al. Anti-inflammatory effects of quercetin in a mouse model of MC903-induced atopic dermatitis. *International Immunopharmacology*. 2019;74:1-11.

